Nonmelanoma skin cancers (NMSC) are a heterogeneous group of cancers that primarily include cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC).1,2

Together, CSCC and BCC comprise approximately 99% of NMSC cases, and are the most common malignancies
in the world.2

Key global statistics for NMSC:

7.7 million cases

estimated worldwide in 20171


of all cancer diagnoses worldwide1

Key US statistics for NMSC:

>3.3 million cases

diagnosed in the United States annually3

1 out of 3

cancers diagnosed in the
United States4

Despite the high incidence of NMSC, only a small number of cases progress to advanced disease.1


Select one of the following to learn more:

References: 1. Hall ET, Fernandez-Lopez E, Silk AW, Dummer R, Bhatia S. Immunologic characteristics of nonmelanoma skin cancers: implications for immunotherapy. Am Soc Clin Oncol Educ Book. 2020;40:398-407. Accessed September 10, 2020. 2. Fahradyan A, Howell AC, Wolfswinkel EM, Tsuha M, Sheth P, Wong AK. Updates on the management of non-melanoma skin cancer (NMSC). Healthcare (Basel). 2017;5(4):1-24. Accessed September 10, 2020. 3. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012. JAMA Dermatol. 2015;151(10):1081-1086. 4. Kansara S, Bell D, Weber R. Surgical management of non melanoma skin cancer of the head and neck. Oral Oncol. 2020;100:1-7.